Effectiveness for remission maintenance rate and safety of different rituximab regimens for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan: a J-CANVAS study
Rituximab (RTX) has been reported to effectively maintain remission in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). In this multicenter study involving 57 patients who achieved remission after 24 weeks, we evaluated the effectiveness of RTX in maintaining remission in patients w...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-01-01
|
| Series: | Immunological Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/25785826.2024.2448912 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841545871434448896 |
|---|---|
| author | Chie Ogita Kazuteru Noguchi Jiro Takeuchi Naoto Azuma Satoshi Omura Daiki Nakagomi Yoshiyuki Abe Masatoshi Kadoya Naoho Takizawa Atsushi Nomura Yuji Kukida Naoya Kondo Yasuhiko Yamano Takuya Yanagida Koji Endo Shintaro Hirata Tohru Takeuchi Kunihiro Ichinose Masaru Kato Ryo Yanai Yusuke Matsuo Yasuhiro Shimojima Ryo Nishioka Ryota Okazaki Tomoaki Takata Takafumi Ito Mayuko Moriyama Ayuko Takatani Yoshia Miyawaki Yutaka Kawahito Toshiko Ito-Ihara Takashi Kida Nobuyuki Yajima Takashi Kawaguchi Kiyoshi Matsui |
| author_facet | Chie Ogita Kazuteru Noguchi Jiro Takeuchi Naoto Azuma Satoshi Omura Daiki Nakagomi Yoshiyuki Abe Masatoshi Kadoya Naoho Takizawa Atsushi Nomura Yuji Kukida Naoya Kondo Yasuhiko Yamano Takuya Yanagida Koji Endo Shintaro Hirata Tohru Takeuchi Kunihiro Ichinose Masaru Kato Ryo Yanai Yusuke Matsuo Yasuhiro Shimojima Ryo Nishioka Ryota Okazaki Tomoaki Takata Takafumi Ito Mayuko Moriyama Ayuko Takatani Yoshia Miyawaki Yutaka Kawahito Toshiko Ito-Ihara Takashi Kida Nobuyuki Yajima Takashi Kawaguchi Kiyoshi Matsui |
| author_sort | Chie Ogita |
| collection | DOAJ |
| description | Rituximab (RTX) has been reported to effectively maintain remission in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). In this multicenter study involving 57 patients who achieved remission after 24 weeks, we evaluated the effectiveness of RTX in maintaining remission in patients with AAV. Patients were divided into three groups based on RTX administration: continuous, induction phase-only, and maintenance phase-only groups. The continuous group had a remission maintenance rate after 48 weeks of treatment compared with the induction phase-only group (100% vs. 88.2%, p = 0.29). More patients in the continuous group received three or more RTX doses during the induction period (82.4% vs. 52.9%, p = 0.06), and this group had a lower incidence of infection (5.9% vs. 29.4%, p = 0.08). Compared with the maintenance-only group, the continuous group had a numerically higher proportion of patients in remission after 48 weeks of treatment (100% vs. 83.3%, p = 0.26) and a lower incidence of infection (5.9% vs. 50%, p = 0.04); however, the N in the maintenance phase was small and suspected to have low power. Regardless of the method of RTX administration (induction phase-only or continuous), administering RTX during the induction phase may be crucial for achieving remission. |
| format | Article |
| id | doaj-art-f5c5490c72a6418e9b34c521e0c5dabf |
| institution | Kabale University |
| issn | 2578-5826 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Immunological Medicine |
| spelling | doaj-art-f5c5490c72a6418e9b34c521e0c5dabf2025-01-11T12:08:21ZengTaylor & Francis GroupImmunological Medicine2578-58262025-01-011810.1080/25785826.2024.2448912Effectiveness for remission maintenance rate and safety of different rituximab regimens for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan: a J-CANVAS studyChie Ogita0Kazuteru Noguchi1Jiro Takeuchi2Naoto Azuma3Satoshi Omura4Daiki Nakagomi5Yoshiyuki Abe6Masatoshi Kadoya7Naoho Takizawa8Atsushi Nomura9Yuji Kukida10Naoya Kondo11Yasuhiko Yamano12Takuya Yanagida13Koji Endo14Shintaro Hirata15Tohru Takeuchi16Kunihiro Ichinose17Masaru Kato18Ryo Yanai19Yusuke Matsuo20Yasuhiro Shimojima21Ryo Nishioka22Ryota Okazaki23Tomoaki Takata24Takafumi Ito25Mayuko Moriyama26Ayuko Takatani27Yoshia Miyawaki28Yutaka Kawahito29Toshiko Ito-Ihara30Takashi Kida31Nobuyuki Yajima32Takashi Kawaguchi33Kiyoshi Matsui34Department of Diabetes, Endocrinology and Clinical Immunology, Hyogo Medical University School of Medicine, Hyogo, JapanDepartment of Diabetes, Endocrinology and Clinical Immunology, Hyogo Medical University School of Medicine, Hyogo, JapanHyogo Medical University Clinical Epidemiology, Hyogo, JapanDepartment of Diabetes, Endocrinology and Clinical Immunology, Hyogo Medical University School of Medicine, Hyogo, JapanInflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, JapanDepartment of Rheumatology, University of Yamanashi Hospital, Yamanashi, JapanDepartment of Internal Medicine and Rheumatology, Juntendo University, Tokyo, JapanCenter for Rheumatic Disease, Japanese Red Cross Society Kyoto Daiichi Hospital, Kyoto, JapanDepartment of Rheumatology, Chubu Rosai Hospital, Aichi, JapanImmuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, JapanDepartment of Rheumatology, Japanese Red Cross Society Kyoto Daini Hospital, Kyoto, JapanDepartment of Nephrology, Kyoto Katsura Hospital, Kyoto, JapanDepartment of Respiratory Medicine and Allergy, Tosei General Hospital, Aichi, JapanDepartment of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, JapanDepartment of General Internal Medicine, Tottori Redcross Hospital, Tottori, JapanDepartment of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, JapanDepartment of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Osaka, JapanDepartment of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, JapanDivision of Rheumatology, Endocrinology and Nephrology, Graduate School of Medicine, Hokkaido University, Hokkaido, JapanDivision of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, JapanDepartment of Rheumatology, Tokyo Kyosai Hospital, Tokyo, JapanDepartment of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, JapanDepartment of Rheumatology, Graduate School of Medical Science, Kanazawa University, Kanazawa, JapanDivision of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago, JapanDivision of Gastroenterology and Nephrology, Tottori University, Yonago, JapanDivision of Nephrology, Department of Internal Medicine, Teikyo University Chiba Medical Center, Chiba, JapanDepartment of Rheumatology, Shimane University Faculty of Medicine, Shimane, JapanRheumatic Disease Center, Sasebo Chuo Hospital, Nagasaki, JapanDepartment of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, JapanInflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, JapanThe Clinical and Translational Research Center, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, JapanInflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, JapanDivision of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, JapanDepartment of Practical Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, JapanDepartment of Diabetes, Endocrinology and Clinical Immunology, Hyogo Medical University School of Medicine, Hyogo, JapanRituximab (RTX) has been reported to effectively maintain remission in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). In this multicenter study involving 57 patients who achieved remission after 24 weeks, we evaluated the effectiveness of RTX in maintaining remission in patients with AAV. Patients were divided into three groups based on RTX administration: continuous, induction phase-only, and maintenance phase-only groups. The continuous group had a remission maintenance rate after 48 weeks of treatment compared with the induction phase-only group (100% vs. 88.2%, p = 0.29). More patients in the continuous group received three or more RTX doses during the induction period (82.4% vs. 52.9%, p = 0.06), and this group had a lower incidence of infection (5.9% vs. 29.4%, p = 0.08). Compared with the maintenance-only group, the continuous group had a numerically higher proportion of patients in remission after 48 weeks of treatment (100% vs. 83.3%, p = 0.26) and a lower incidence of infection (5.9% vs. 50%, p = 0.04); however, the N in the maintenance phase was small and suspected to have low power. Regardless of the method of RTX administration (induction phase-only or continuous), administering RTX during the induction phase may be crucial for achieving remission.https://www.tandfonline.com/doi/10.1080/25785826.2024.2448912Anti-neutrophil cytoplasmic antibody-associated vasculitisinduction phase of remissionmaintenance phase of remissionregular administrationrituximab |
| spellingShingle | Chie Ogita Kazuteru Noguchi Jiro Takeuchi Naoto Azuma Satoshi Omura Daiki Nakagomi Yoshiyuki Abe Masatoshi Kadoya Naoho Takizawa Atsushi Nomura Yuji Kukida Naoya Kondo Yasuhiko Yamano Takuya Yanagida Koji Endo Shintaro Hirata Tohru Takeuchi Kunihiro Ichinose Masaru Kato Ryo Yanai Yusuke Matsuo Yasuhiro Shimojima Ryo Nishioka Ryota Okazaki Tomoaki Takata Takafumi Ito Mayuko Moriyama Ayuko Takatani Yoshia Miyawaki Yutaka Kawahito Toshiko Ito-Ihara Takashi Kida Nobuyuki Yajima Takashi Kawaguchi Kiyoshi Matsui Effectiveness for remission maintenance rate and safety of different rituximab regimens for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan: a J-CANVAS study Immunological Medicine Anti-neutrophil cytoplasmic antibody-associated vasculitis induction phase of remission maintenance phase of remission regular administration rituximab |
| title | Effectiveness for remission maintenance rate and safety of different rituximab regimens for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan: a J-CANVAS study |
| title_full | Effectiveness for remission maintenance rate and safety of different rituximab regimens for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan: a J-CANVAS study |
| title_fullStr | Effectiveness for remission maintenance rate and safety of different rituximab regimens for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan: a J-CANVAS study |
| title_full_unstemmed | Effectiveness for remission maintenance rate and safety of different rituximab regimens for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan: a J-CANVAS study |
| title_short | Effectiveness for remission maintenance rate and safety of different rituximab regimens for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan: a J-CANVAS study |
| title_sort | effectiveness for remission maintenance rate and safety of different rituximab regimens for treating anti neutrophil cytoplasmic antibody associated vasculitis in japan a j canvas study |
| topic | Anti-neutrophil cytoplasmic antibody-associated vasculitis induction phase of remission maintenance phase of remission regular administration rituximab |
| url | https://www.tandfonline.com/doi/10.1080/25785826.2024.2448912 |
| work_keys_str_mv | AT chieogita effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT kazuterunoguchi effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT jirotakeuchi effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT naotoazuma effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT satoshiomura effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT daikinakagomi effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT yoshiyukiabe effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT masatoshikadoya effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT naohotakizawa effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT atsushinomura effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT yujikukida effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT naoyakondo effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT yasuhikoyamano effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT takuyayanagida effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT kojiendo effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT shintarohirata effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT tohrutakeuchi effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT kunihiroichinose effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT masarukato effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT ryoyanai effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT yusukematsuo effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT yasuhiroshimojima effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT ryonishioka effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT ryotaokazaki effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT tomoakitakata effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT takafumiito effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT mayukomoriyama effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT ayukotakatani effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT yoshiamiyawaki effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT yutakakawahito effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT toshikoitoihara effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT takashikida effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT nobuyukiyajima effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT takashikawaguchi effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy AT kiyoshimatsui effectivenessforremissionmaintenancerateandsafetyofdifferentrituximabregimensfortreatingantineutrophilcytoplasmicantibodyassociatedvasculitisinjapanajcanvasstudy |